Kiniksa approves KPL-387 LTIP for execs, grants PSUs and options tied to BLA submission and FDA approval

Kiniksa Pharmaceuticals International, plc

Compensation Committee approved KPL-387 Long-Term Incentive Plan for executive officers, linked to BLA submission (Milestone 1) and FDA approval (Milestone 2) for recurrent pericarditis treatment.
CEO Sanj Patel granted 16,312 PSUs and 26,142 options; CFO Mark Ragosa granted 9,309 PSUs and 14,918 options.
Awards include cash, PSUs, and options, with earnout percentages (100%, 75%, 50%, 0%) based on milestone achievement dates.
If a change in control occurs, unvested awards may accelerate under specified conditions, including termination without cause or resignation for good reason.
The plan covers five named executive officers; cash award amounts are based on base salary at milestone achievement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.